The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

• DOI: 10.1016/j.jiph.2024.04.016
• Publication Date: 2024-04-21T14:22:43Z
• Authors: Abdulaziz Boqaeid; Laila Layqah; Amgad Alonazy; Mutaz Althobaiti; Al-zahraa Almahlawi; Abdullah Al-Roqy; Omar Baharoon; Abdullah Alsaeedi; Jinan Shamou; Salim Baharoon
• Keywords: Tocilizumab

The risk of infection including tuberculosis (TB) or reactivation during biological therapy with the current various clinical application is a major concern. This may be higher in countries endemic to TB. Our aim this study determine TB patients receiving 3 treatments, Adalimumab, Etanercept and Tocilizumab. A retrospective cohort extending over 2 years follow-up for all Tocilizumab indications tertiary care center Saudi Arabia. Over period 2015-2019, total 410 received 271 58 Rheumatoid arthritis was most common indication groups Adalimumab inflammatory bowel disease, psoriatic juvenile idiopathic arthritis. After mean follow up 36±8.9 months 21.5 ± 8.4 21±2.5 there were no reported cases groups. Only one patient diagnosed latent 7 later after starting tow Etanercept. overall Interferon Gamma Release Assays (IGRA) positivity rate 9.7%. There significant association between IGRA age. cutoff age which has significantly increased 53.20 years. In our study, Etanercept, had infection. 0.3% treated 0.9% converted positive therapy.